Brain : a journal of neurology · 2009
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Palazuelos Javier, Aguado Tania, Pazos M Ruth, Julien Boris, Carrasco Carolina, Resel Eva, Sagredo Onintza, Benito Cristina, Romero Julián, Azcoitia Iñigo, Fernández-Ruiz Javier, Guzmán Manuel, Galve-Roperh Ismael
Аннотация
Cannabinoid-derived drugs are promising agents for the development of novel neuroprotective strategies. Activation of neuronal CB(1) cannabinoid receptors attenuates excitotoxic glutamatergic neurotransmission, triggers prosurvival signalling pathways and palliates motor symptoms in animal models of neurodegenerative disorders. However, in Huntington's disease there is a very early downregulation of CB(1) receptors in striatal neurons that, together with the undesirable psychoactive effects triggered by CB(1) receptor activation, foster the search for alternative pharmacological treatments. Here, we show that CB(2) cannabinoid receptor expression increases in striatal microglia of Huntington's disease transgenic mouse models and patients. Genetic ablation of CB(2) receptors in R6/2 mice, that express human mutant huntingtin exon 1, enhanced microglial activation, aggravated disease symptomatology and reduced mice lifespan. Likewise, induction of striatal excitotoxicity in CB(2) receptor-deficient mice by quinolinic acid administration exacerbated brain oedema, microglial activation, proinflammatory-mediator state and medium-sized spiny neuron degeneration. Moreover, administration of CB(2) receptor-selective agonists to wild-type mice subjected to excitotoxicity reduced neuroinflammation, brain oedema, striatal neuronal loss and motor symptoms. Studies on ganciclovir-induced depletion of astroglial proliferation in transgenic mice expressing thymidine kinase under the control of the glial fibrillary acidic protein promoter excluded the participation of proliferating astroglia in CB(2) receptor-mediated actions. These findings support a pivotal role for CB(2) receptors in attenuating microglial activation and preventing neurodegeneration that may pave the way to new therapeutic strategies for neuroprotection in Huntington's disease as well as in other neurodegenerative disorders with a significant excitotoxic component.
Предметные рубрики MeSH
AnimalsAnti-Bacterial AgentsBiomarkersCorpus StriatumHumansHuntingtin ProteinHuntington DiseaseMagnetic Resonance ImagingMaleMiceMice, Inbred C57BLMice, KnockoutMicrogliaMinocyclineNerve DegenerationNerve Tissue ProteinsNeuroprotective AgentsNuclear ProteinsQuinolinic AcidReceptor, Cannabinoid, CB2Rotarod Performance TestSeizures